Treatment of inflammatory bowel disease using growth factors
CA 2428084 A1 · Owner: Lichenstein, Henry S. · Inventors: Rittman, B.; Lichenstein, Henry S.; Larochelle, William J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotide sequences and the FGF-CX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof are claimed in , the invention. Similarly methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences or variants, fragments and homologs thereof alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 6, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 6, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 6, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.